Alzheimer's disease (AD) is a neurodegenerative disease that primarily affects older adults and is characterized by progressive memory loss and cognitive dysfunction. The disease is the most common type of dementia worldwide and imposes a significant burden on patients, families and society. More than 50 million people worldwide are affected by Alzheimer's disease, placing enormous financial strain on healthcare systems and families. The main molecular metabolic pathways of Alzheimer's disease include amyloid beta protein metabolic pathway and tau protein phosphorylation pathway. Abnormal accumulation of amyloid beta protein in the brain to form plaques, and excessive phosphorylation of tau protein to form neurofibrillary tangles, these pathological changes lead to nerve cell damage and death, resulting in the gradual loss of cognitive function. Current treatments can only slow the progression of the disease or alleviate symptoms and cannot completely cure AD. Finding effective treatment and intervention strategies can not only significantly improve the quality of life of Alzheimer's patients, but also reduce the burden of the disease on society and families. This article will review the background and epidemiology of Alzheimer's disease, discuss its main molecular metabolic pathways in detail, and review the current status of treatment, with a view to providing references for future research and treatment strategies.
Read full abstract